{"nctId":"NCT00176878","briefTitle":"Stem Cell Transplant for Bone Marrow Failure Syndromes","startDateStruct":{"date":"2000-06"},"conditions":["Diamond-Blackfan Anemia","Kostmann's Neutropenia","Shwachman-Diamond Syndrome"],"count":10,"armGroups":[{"label":"Bone Marrow Failure Disorders","type":"EXPERIMENTAL","interventionNames":["Procedure: Stem cell transplant","Drug: Fludarabine monophosphate","Procedure: Total lymphoid irradiation","Drug: Busulfan","Biological: anti-thymocyte globulin"]}],"interventions":[{"name":"Stem cell transplant","otherNames":["BMT"]},{"name":"Fludarabine monophosphate","otherNames":["Fludara"]},{"name":"Total lymphoid irradiation","otherNames":["TLI"]},{"name":"Busulfan","otherNames":["Busulfex"]},{"name":"anti-thymocyte globulin","otherNames":["ATG"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients eligible for transplantation under this protocol will be \\<35 years of age, and will be diagnosed with:\n\n  * a bone marrow failure syndrome unresponsive to available therapy, including but not limited to Diamond-Blackfan anemia, Shwachman Diamond syndrome or Kostmann's neutropenia but exclusive of aplastic anemia.\n* Diamond Blackfan Anemia:\n\n  * Patients must show evidence of steroid resistance requiring equivalent of \\>6 transfusions yearly despite steroid therapy.\n  * Evidence of developing aplasia or myelodysplasia will also be criteria for transplantation.\n* Kostmann's Neutropenia, Shwachman-Diamond syndrome:\n\n  * Patients must have been previously diagnosed as having a clinical picture characteristic of Shwachman-Diamond syndrome (exocrine pancreatic insufficiency, growth retardation, metaphyseal dysostosis, neutropenia), or must have a bone marrow aspirate consistent with Kostmann's neutropenia, with no evidence of acute leukemia.\n  * Patients must have failed therapy with granulocyte-colony stimulating factor (G-CSF), as determined by an inability to maintain an absolute neutrophil count (ANC) \\>750 cells/ml(3), or manifesting recurrent infections despite G-CSF administration resulting in life threatening infections or repeated hospitalizations (\\<4 /year).\n\nExclusion Criteria:\n\n* Patients \\>35 years of age\n* Karnofsky score \\<70%\n* Hepatic dysfunction as determined by bilirubin \\>3.0, ALT \\>150, or active hepatitis\n* Pulmonary function tests with forced volume vital capacity (FVC) and forced expiratory volume (FEV) \\<70%; O2 saturation \\<94%\n* Renal dysfunction with glomerular filtration rate (GFR) \\<30% of predicted.\n* Cardiac compromise, with left ejection fraction \\<45%.\n* Severe, stable neurologic impairment.\n* Human immunodeficiency virus (HIV) positivity.\n* Pregnant or lactating females","healthyVolunteers":false,"sex":"ALL","maximumAge":"35 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Alive (Survival) at 2 Years","description":"Calculated from day 1 of transplant to last contact.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Alive at Three Years (Survival)","description":"Number of subjects who survived 3 years post-transplant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Succcessful Engraftment After Transplantation","description":"Number of patients who received non-genotypic identical marrow or cord blood cells using a \"non-myeloablative\" preparative regimen and exhibited engraftment at Day 42.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Grade 2-4 Acute Graft Versus Host Disease","description":"Number of patients with Grade 2, 3 and 4 Acute (normally observed within the first 100 days) Graft Versus Host Disease. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Chronic Graft Versus Host Disease","description":"Number of patients who exhibited chronic (normally occurs after 100 days) Graft Versus Host Disease at 2 years post transplant. Chronic graft-versus-host-disease, over its long-term course, can also cause damage to the connective tissue and exocrine glands.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Disease Recurrence","description":"Number of patients who exhibited disease recurrence at 2 years.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":10},"commonTop":[]}}}